Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Tampa, Florida

Phase 1 cancer trials in Tampa, FL

74 Phase 1 cancer studies are recruiting participants at sites in Tampa as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Tampa at a glance

  • 74 studies are recruiting at a site in Tampa.
  • By phase: Early Phase 1 (2), Phase 1 (33), Phase 1/2 (39).
  • By sponsor: industry (61), university, hospital or other (11), government (2).
  • By research area: Lung Cancer (26), Breast Cancer (23), Lymphoma (14), Prostate Cancer (7), Melanoma (3), Pancreatic Cancer (1).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Tampa

Basic details from each study's public record (the 30 most recently updated of 74). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Aktis Oncology, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07020117 · updated
  2. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    H. Lee Moffitt Cancer Center and Research Institute
    Registry record
    NCT06324357 · updated
  3. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06638307 · updated
  4. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    Moffitt Cancer Center
    Registry record
    NCT05315700 · updated
  5. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Moffitt
    Registry record
    NCT07114601 · updated
  6. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Moffitt
    Registry record
    NCT07213791 · updated
  7. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07100106 · updated
  8. A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Cogent Biosciences, Inc.
    Study site
    H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
    Registry record
    NCT07383506 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Lung cancer studies recruiting in Tampa

  1. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06983743 · updated
  2. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07277413 · updated
  3. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Moffit Cancer Center
    Registry record
    NCT07111520 · updated
  4. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07458347 · updated
  5. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06706076 · updated
  6. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Obsidian Therapeutics, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06060613 · updated
  7. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  8. Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Molecular Partners AG
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07278479 · updated
  9. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    H Lee Moffitt Cancer Center and Research Institute
    Registry record
    NCT06162221 · updated
  10. AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Avenzo Therapeutics, Inc.
    Study site
    Avenzo Therapeutics Recruiting Site
    Registry record
    NCT07038343 · updated
  11. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07070232 · updated
  12. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Bicara Therapeutics
    Study site
    H. Lee Moffitt Cancer Center and Research Institute, Inc
    Registry record
    NCT04429542 · updated
  13. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #8
    Registry record
    NCT05176483 · updated
  14. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06362252 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Prostate cancer studies recruiting in Tampa

  1. A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Moffitt Cancer Center - McKinley Drive
    Registry record
    NCT03972657 · updated
  2. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06879041 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Lymphoma studies recruiting in Tampa

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Saint Joseph's Hospital/Children's Hospital-Tampa
    Registry record
    NCT04726241 · updated
  2. Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06015880 · updated
  3. A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06697184 · updated
  4. A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06090539 · updated
  5. AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06137118 · updated
  6. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Tampa General Hospital Cancer Institute
    Registry record
    NCT05006716 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Tampa, FL on ClinicalTrials.gov.

Ask about studies near Tampa

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call